www.shire.com
Shire Plc is a specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician. Shire focuses its business on attention deficit and hyperactivity disorder (ADHD), human genetic therapies (HGT), gastrointestinal (GI) and renal diseases.
News
-
10/01/12
Shire acquires rights to develop Resolor in US -
18/11/11
Shire inks co-development deal for ADHD drugs in Japan -
02/02/11
Shire's Vyvanse drug approved by Health Canada for adolescents and adults -
10/01/11
Shire finds Vyvanse drug has potential for new treatment of sleep disorder -
09/09/10
Shire gains exclusive rights to Acceleron's molecules outside of NA that treat muscular disorders -
03/09/09
Shire gets US FDA approval for INTUNIV ADHD treatment -
16/03/09
Shire plc files lawsuit against Barr Laboratories for patent infringement
Recent Sector News
-

Dow seen opening higher ahead of jobless data, Facebook, Hewlett-Packard in focus
U.S. equity markets looked set to point to open higher Thursday after strong earnings from Hewlett-Packard (NYSE:HPQ), and as talks progress on Greece's debt crisis.
-

Q1 gold demand underpinned by China, Central Banks and ETFs
Global gold demand in the first quarter of 2012 was 1,097.6 tonnes, down 5 percent from the high demand levels seen a year earlier, according to the World Gold Council.
-

Medgenics cleared by FDA to begin Phase IIb clinical trials for EPODURE; shares up
Biopharmaceutical company Medgenics (LON:MEDG, AMEX:MDGN) achieved a major milestone today - with clearance to begin a phase IIb trial of EPODURE to treat anaemia in kidney failure patients.
-

Facebook boosts public offering by 25%
Social network site Facebook Wednesday increased the size of its initial public offering by almost 25 per cent as it could raise as much as $16 billion on strong investor demand for its market debut.
-

Snipp plans ambitious growth as mobile marketing takes off
Mobile marketing company Snipp (CVE:SPN) (TSX.V:SPN), which recently listed on the TSX Venture Exchange, is now seeking a listing on the OTC exchange as it continues to grow in a space that is seeing more and more traction from companies looking to boost their marketing efforts.
-

Facebook ups IPO price range
Facebook has increased the price range in Silicon Valley's biggest-ever initial public offering to raise more than $12 billion, giving the social network a valuation potentially exceeding $100 billion.
What do others think of Shire Plc
Investors interested in Shire Plc recently viewed
-
Eco Animal Health Group Plc (AIM: EAH) ECO Animal Health - applying science carefully to animal health markets -
NeoStem (NYSE AMEX: NBS) . -
Uluru (AMEX: ULU) . -
e-Therapeutics plc (AIM: ETX) Systems Biology Drug Discovery -
Oxford Pharmascience (AIM: OXP) Developing proprietary delivery systems for medicines & supplements



















